SCHEMBL4233285

SCHEMBL4233285

O=c1c2ccccc2nc(-c2ccc(C(F)(F)F)cc2)n1NCc1ccc(Br)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
NPSR1 Q6W5P4 2/20 0.55
EGFR P00533 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
ALDH1A1 P00352 4/20 0.52
CYP1A2 P05177 3/20 0.52
CYP2D6 P10635 3/20 0.52
CYP2C9 P11712 3/20 0.52
CYP2C19 P33261 3/20 0.52
GAA P10253 2/20 0.52
CYP3A4 P08684 2/20 0.49
LMNA P02545 4/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
POLB P06746 1/20 0.48
HTT P42858 3/20 0.47
HDAC6 Q9UBN7 1/20 0.46
HPGD P15428 1/20 0.45
KDM4E B2RXH2 1/20 0.45
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237693 0.91 SMN1; SMN2 (0.64) MAPTNPSR1SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL4233257 0.90 ALDH1A1 (0.53) MAPTNPSR1EGFRSMN1; SMN2ALDH1A1
SCHEMBL4245035 0.89 EGFR (0.62) MAPTNPSR1EGFRSMN1; SMN2ALDH1A1
SCHEMBL4236185 0.88 SMN1; SMN2 (0.67) MAPTNPSR1EGFRSMN1; SMN2ALDH1A1
SCHEMBL4237311 0.86 ALDH1A1 (0.58) MAPTNPSR1EGFRSMN1; SMN2ALDH1A1
SCHEMBL4244207 0.86 MAPT (0.62) MAPTNPSR1EGFRSMN1; SMN2ALDH1A1
SCHEMBL4242316 0.84 MAPT (0.55) MAPTNPSR1EGFRSMN1; SMN2ALDH1A1
SCHEMBL4233237 0.83 MAPT (0.57) MAPTNPSR1EGFRSMN1; SMN2ALDH1A1
SCHEMBL4233391 0.83 CYP1A2 (0.49) MAPTNPSR1EGFRSMN1; SMN2ALDH1A1
SCHEMBL4241971 0.83 MEN1 (0.55) MAPTNPSR1EGFRSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 MAPT 4430/4885NPSR1 981/4885EGFR 4597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.